About TB-500 - Cellular Level Repair Peptide

TB-500 is a short synthetic fragment of Thymosin Beta-4 that promotes cell migration and blood vessel growth, making it incredible for repairing muscle tears, connective tissues, and reducing systemic inflammation.

WHAT THE RESEARCH SHOWS

Research on TB-500 (the active fragment of the naturally occurring peptide Thymosin Beta-4) centers on its powerful systemic tissue repair and mobility benefits:
* Actin Regulation & Cell Migration: It upregulates actin, an essential cellular building block. This allows repair cells (like fibroblasts and endothelial cells) to migrate rapidly to damaged sites to jump-start tissue regeneration.
* Angiogenesis (New Blood Flow): TB-500 stimulates the formation of new micro-vessels. This is crucial for hard-to-heal connective tissues like tendons and ligaments which naturally suffer from poor blood circulation.
* Anti-Fibrotic & Scar Reduction: Studies show it downregulates excessive myofibroblasts, preventing thick scar tissue or adhesions from forming in injured muscles and joints.
* Systemic Mobility: Unlike purely localized healers, TB-500 circulates through the entire vascular system, reducing chronic stiffness, inflammation, and muscle tears body-wide.
While TB-500 is great on its own, it's rarely run solo in recovery research. It pairs synergistically with BPC-157 in the WOLVERINE combo for focused joint and tendon repair, or in the 3-in-1 GLOW combo (BPC-157, TB-500, and GHK-Cu) for complete tissue remodeling, reduced inflammation, and better value. While it is solid solo, it works best paired with other healing peptides like the WOLVERINE combo (BPC-157 + TB-500) for fast injury repair, or the 4-in-1 KLOW combo (BPC-157 + TB-500 + GHK-Cu +KPV) for comprehensive joint, muscle, Gut and tissue recovery.

STUDIES

• Bock-Marquette and colleagues found Tβ4 activates a cell-survival pathway (ILK/Akt), helps heart muscle cells survive and migrate, and improves heart function after a heart attack in mice.
• A 2007 follow-up showed Tβ4 activates repair cells from the heart’s outer layer (the epicardium) and grows new blood vessels in the injured heart.
• Eye: Phase 3 (SEER-1, 2023). RGN-259 eye drops (0.1% Tβ4) healed corneal defects faster, improved eye comfort and were safe in neurotrophic keratopathy (a rare disease where damaged corneal nerves stop the surface of the eye healing).
  • 6 of 10 treated patients healed completely at 4 weeks, versus 1 of 8 on placebo. By day 43 the difference was statistically significant.
• Eye: Phase 2 (2010). 58% of treated patients healed completely at 28 days, versus 28% on placebo.
• Eye: further trials. A Phase 2 trial in severe dry eye followed. A European Phase 3, SEER-3 (70 patients across Europe, the UK and the US), is approved through the NHS Health Research Authority.
• Skin ulcers (2009). In pressure-ulcer and venous leg-ulcer trials, the middle dose of a Tβ4 gel appeared to start wound healing faster than placebo.

LINKS

• Superpower – TB-500 guide
• Peptide Protocol Wiki – TB-500 research
• Outliyr – TB-500 report
• Outliyr – TB-500 (cancer and WADA)
• Wikipedia – TB-500

Lyophilised powder